CERo Therapeutics Holdings, Inc. - Common Stock CERO 深 沪

Maxim Group Downgrades CERo Therapeutics Hldgs to Hold

Maxim Group analyst Jason McCarthy downgrades CERo Therapeutics Hldgs (NASDAQ:CERO) from Buy to Hold.

11-04 03:07

协鑫集团首席可持续发展官宋贇波：直面海外监管挑战 以ESG深度实践构筑核心竞争力

登录新浪财经APP 搜索【信披】查看更多考评等级 专题：2025可持续全球领导者大会&首届绿色产业与可持续消费博览会 　　2025可持...

10-18 17:23

CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236

CERo Therapeutics Holdings, Inc. reports the successful completion of the initial evaluation of the first patient in its Phase 1 clinical trial for CER-1236, with no dose-limiting toxicities observed. The company plans to dose the second patient shortly and is preparing to initiate a second trial in solid tumors later this year.

06-23 12:15

【美股盤前】利率決議前夕，美指期貨漲跌互見！台積電2nm技術壓倒三星，股價狂飆逾1%！

聯准會公佈利率決議前夕，美指期貨漲跌不一；台積電2nm工藝良率遠超三星，股價盤前大漲逾1%；美參議院通過GENIUS法案，加密貨幣概念股盤前上漲。

06-18 11:40

CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML)

CERo Therapeutics Holdings, Inc. announced that its lead drug candidate CER-1236 received FDA's Orphan Drug Designation for treating acute myeloid leukemia (AML). Currently in Phase 1 clinical trials, CER-1236 uses engineered T cells with phagocytic mechanisms to target AML patients with relapsed, refractory, or newly diagnosed conditions.

06-17 12:15

【美股盤前】伊以衝突推升石油股狂飆！SK海力士股價創20年新高！美國經濟數據即將揭曉，美股能否再創新高？

伊以衝突持續，石油股繼續受益大漲；SK海力士擬建造韓國最大AI數據中心，股價創下近20年新高；美國即將公佈多項經濟數據，美股將繼續上漲？

06-17 11:33

CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split

06-11 13:10

CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing

CERo Therapeutics Holdings, Inc. issued additional Series D Preferred Stock worth up to $3 million to investors, bringing total issuance to $8 million. CEO Chris Ehrlich highlighted investor confidence and progress with CAR-T candidate CER-1236, which recently achieved first-in-human dosing. Proceeds will support ongoing and new clinical trials for hematological malignancies and tumor types.

06-06 12:15

CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company’s Lead Compound CER-1236

CERo Therapeutics announced three new patents, including U.S. Patents No. 12,291,557 and No. 12,303,551, and a European patent application, expanding their intellectual property portfolio for their chimeric engulfment receptor T cell (CER-T) technology targeting cancer treatments.

06-02 13:05

CERo Therapeutics Holdings, Inc. Doses First Patient with CER-1236 in Phase 1 Clinical Trial for Acute Myeloid Leukemia and is Advancing Through Protocol-Defined Evaluations

CERo Therapeutics dosed the first patient in its Phase 1 clinical trial of CER-1236 for acute myeloid leukemia (AML). The study, evaluating safety and efficacy, will be presented at the 2025 American Society of Clinical Oncology meeting. The first-in-human trial aims to determine the highest tolerated dose and assess outcomes like adverse events and response rates.

05-30 12:15